2016 Financial Year Summary: 2017 Financial Year Summary:
  • Dose sales: 11,931, up 16.4%
  • Revenue: $232.5 million, up 32.0%
  • Reported net profit after tax: $53.6 million, up 32.8%
  • R&D investment: $10.8 million, up 25.4%
  • Clinical investment: $20.6 million, up 0.9%
  • Cash: $107.0 million, up 44.7%
  • Reported earnings per share: 93.7 cents, up 31.3%
  • Dividend: 30.0 cents, up 50.0%
  • Dose sales: 12,578, up 5.4%
  • Revenue: $234.3 million, up 0.8%
  • Underlying net profit after tax: $42.4 million, down 20.9%
  • Reported net loss after tax: $26.3 million, down 149.0%
  • R&D investment: $11.9 million, up 9.5%
  • Clinical investment: $24.9 million, up 20.5%
  • Cash: $118.3 million, up 10.6%
  • Underlying earnings per share: 73.5 cents, down 21.6%
  • Reported earnings per share: -45.5 cents, down 148.6%
  • Dividend: 30.0 cents, up 0.0%

NOTE: All amounts are Australian dollars.



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×